Biocept (NASDAQ:BIOC) has entered into a Software License and Laboratory Data Supply Agreement with Prognos, Inc.
Under the agreement, Biocept will supply de-identified data from its liquid biopsy testing to Prognos, to help its clients ensure that the right patients receive the right therapies.
Biocept will utilize Prognos’ Opal de-identification software to collect and transmit the data to Prognos.
Financial terms are not disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.